newsfilter
← Latest News
Business Wire·

AlloVir Reports Third Quarter 2023 Financial Results

-- Posoleucel, a highly innovative off-the-shelf, multi-virus-specific investigational T cell therapy, continues to advance in three distinct, Phase 3, first-to-market indications in immunocompromised patients --